FDA: GRANTS ACCELERATED APPROVAL TO RYBREVANT FASPRO FOR RECURRENT OR METASTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA

Reuters · 3d ago

Please log in to view news